Mecox CureMed and Boryung Pharmaceutical Join Hands for Joint Development of 'Nano Anticancer Drug'

[Asia Economy Reporter Jang Hyowon] Medycox, a KOSDAQ-listed company, and its subsidiary specializing in new drug development, Mecox Curemed, which holds the largest shareholder status, are collaborating with Boryung Pharmaceutical to jointly develop a ‘nano anticancer drug’.

Mecox Curemed recently announced on the 6th that it signed a ‘joint anticancer drug business development agreement’ with Boryung Pharmaceutical. Mecox Curemed plans to accelerate the research and development process of the ‘nano anticancer drug’ applying its self-developed ‘dual-encapsulation liposome platform’ technology by forming an alliance with Boryung Pharmaceutical. The joint R&D project also includes Mecox Curemed’s orally administered blood cancer treatment drug under development, ‘Mecbentu’.

The ‘nano anticancer drug’ jointly developed by Mecox Curemed and Boryung Pharmaceutical is a next-generation anticancer agent applying the ‘dual-encapsulation liposome platform’ technology, which encapsulates two or more drugs in dual nanoparticles to deliver them to cancer cells, currently preparing for preclinical trials. It is explained that the particles themselves have no biological toxicity, and since substances with different drug characteristics can be encapsulated and delivered together, it offers excellent drug release control, delivery effects, and outstanding stability.

Another jointly developed anticancer drug, ‘Mecbentu’, is a new drug independently developed by Mecox Curemed that significantly increases patient convenience by changing the administration route of the existing blood cancer treatment drug ‘Bendamustine’ from an injectable to an oral form. ‘Mecbentu’ received approval for its Phase 1 clinical trial plan (IND) from the Ministry of Food and Drug Safety in April.

Dr. Ilgu Lee of Mecox Curemed stated, “Boryung Pharmaceutical’s global clinical development and marketing experience can play a pivotal role in the rapid global commercialization of Mecox Curemed’s anticancer drug pipeline,” adding, “We plan to maximize the synergy between the two companies and strive for innovative new drug development.”

This content was produced with the assistance of AI translation services.